Alopecia Areata Clinical Trial
Official title:
Assessment of Efficacy and Safety of Sodium Valproate -Loaded Nanospanlastics in Patients With Patchy Alopecia Areata in Comparison to Conventional Therapy With Topical Steroids: a Randomized Controlled Study, With Clinical, Dermoscopic and Molecular Asessements
Verified date | June 2023 |
Source | Kasr El Aini Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
the aim of this study is to assess the efficacy and safety of sodium valproate-loaded nanospanlastic in the treatment of patchy AA, in comparison to conventional therapy with topical steroids
Status | Completed |
Enrollment | 67 |
Est. completion date | April 1, 2023 |
Est. primary completion date | January 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: - Patients with mild to moderate patchy alopecia areata, which is defined as less than 50% involvement of the entire scalp - Age above 12 years. - Both genders. - Patients with patchy alopecia areata, with 2 patches or more Exclusion Criteria: - Patients having single patch alopecia areata (at least 2 patches are required, as one patch will be left untreated to exclude the possibility of spontaneous remission) - Affection of more than 50% of the scalp area - Patients with alopecia totalis or universalis - Patients with ophiasis - Age: Less than 12 years old. - Pregnant or lactating females - Patients with history of or existing scalp skin diseases, infections or skin cancer - Severe systemic illness (as uncontrolled DM or hypertension, liver or renal diseases) and immune-compromised patients - Patients with concomitant autoimmune diseases as suspected by history or confirmed by previous investigations - Diagnosis or history of local dermatological disease in the scalp apart from AA such as eczema, seborrheic dermatitis, psoriasis. - Any psychiatric illness or psychological state impairing future compliance or influencing expectations of the patient |
Country | Name | City | State |
---|---|---|---|
Egypt | Kasralainy Hospital, Dermatology Department | Cairo |
Lead Sponsor | Collaborator |
---|---|
Kasr El Aini Hospital |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | - Treatment success | defined by achieving = 50% reduction in baseline SALT score at end-of-study and/or achieving patient global assessment of improvement (PGAI) = 50%. | 6 months | |
Secondary | molecular Assessment of treatment success rate of SV-loaded nanospanlastics in the treatment of mild to moderate patchy AA in comparison to conventional therapy with topical steroids | Assessment of expression of both beta-catenin and Axin2 in lesional scalp of patients with patchy AA before and after treatment with sodium valproate-loaded nanospanlastics, in comparison to conventional therapy with topical steroids | 3 months | |
Secondary | Dermoscopic evaluation of hair regrowth | This evaluation will determine the number of dystrophic hairs in the patch area at baseline to be compared after the end of treatment. Markers for dystrophic hairs include exclamation-mark hairs, black dots, yellow dots and pigtail regrowing hair. The percentage of dystrophic hairs will be evaluated on a four-point scale: 3, > 50%; 2, 30-50%; 1, 1-29%; 0, no dystrophic hairs | 3 months | |
Secondary | Patient global assessment of improvement | Patient global assessment of improvement will be evaluated at the end of study, and will be scored as the following; (0 =no regrowth; 1 = <25% of regrowth; 2 = 25%-49% of regrowth; 3 = 50%-74% of regrowth; 4 = 75%-99% of re- growth; 5 = 100% of regrowth) | 3 months | |
Secondary | Clinical satisfaction of each patient | Clinical satisfaction of each patient will be made using a 10-point visual analogue scale (VAS, 0-10; the 0 level was defined as "Not satisfied at all," while a level of 10 was defined as "completely satisfied") | 3 months | |
Secondary | Subjective assessment of any encountered adverse effects | Subjective assessment of any encountered adverse effects (burning, itching) will also be performed. This will be determined on a four-point scale: 3, strong sensation; 2, moderate sensation; 1, mild sensation; 0, no itching or burning sensation | 3 months | |
Secondary | Patient satisfaction regarding characteristics of the used topical treatment | Patient satisfaction regarding characteristics of the used topical treatment, for example (texture, spreadability, hair matting, odour). This will be evaluated on a 3-point scale; 0=unsatisfied, 1=moderately satisfied, 2=extremely satisfied | 3 months | |
Secondary | Dermatology Life Quality Index (DLQI) | Dermatology Life Quality Index (DLQI) will be evaluated at baseline and at the end of therapy, using a validated DLQI questionaire | 3 months | |
Secondary | Assessment of relapse | Patients who achieved 100% reduction in baseline SALT after 3 months of treatment (end of therapy) were followed up for additional 3 months (end of study) to monitor any relapses. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05051761 -
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
|
Phase 3 | |
Active, not recruiting |
NCT03570749 -
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
|
Phase 2/Phase 3 | |
Completed |
NCT02812342 -
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
|
Phase 2 | |
Completed |
NCT02350023 -
Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata
|
Phase 4 | |
Completed |
NCT02018042 -
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
|
Phase 2 | |
Terminated |
NCT01898806 -
Intralesional Steroids in the Treatment of Alopecia Areata
|
Phase 4 | |
Recruiting |
NCT04011748 -
Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
|
Phase 2 | |
Terminated |
NCT04517864 -
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
|
Phase 2 | |
Not yet recruiting |
NCT05803070 -
Topical Cetirizine in Treatment of Localized Alopecia Areata
|
||
Not yet recruiting |
NCT05496426 -
A Study of KL130008 in Adults With Severe Alopecia Areata
|
Phase 2 | |
Completed |
NCT04147845 -
Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata
|
N/A | |
Terminated |
NCT03325296 -
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
|
Phase 2 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Enrolling by invitation |
NCT05745389 -
CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
|
||
Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT06087796 -
Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.
|
Phase 1 | |
Withdrawn |
NCT03532958 -
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
|
Phase 2 | |
Recruiting |
NCT02604888 -
Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females
|
N/A | |
Terminated |
NCT01385839 -
Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata
|
N/A | |
Completed |
NCT00408798 -
Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin
|
N/A |